Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

granulomatosis

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

The initiative wants to increase the global use of biosimilars by at least 30% by 2030

- PMLiVE

Roche’s Polivy receives EC approval for lymphoma therapy

The combination therapy is for patients with previously untreated diffuse large B-cell lymphoma

Roche Basel Switzerland

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

Roche Basel Switzerland

Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program

The company renewed its pledge to provide preventative treatment until 2028 for haemophilia A patients

Roche Basel Switzerland

Roche’s Evrysdi improves survival rates for infants with SMA

The study showed the drug reduced serious adverse events and hospitalisations

Roche Basel Switzerland

Roche shares new positive Ocrevus data for MS patients

The CONSONANCE trial showed treatment with Ocrevus resulted in a majority of patients experiencing no disease progression

- PMLiVE

AZ’s Saphnelo receives EU approval for systemic lupus erythematosus

There are an estimated 250,000 people living with SLE in Europe and this is the first new drug to gain EU approval in over ten years

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

EU flag

EMA establishes DARWIN EU Coordination Centre

The new centre will give the EMA and other EU member states access to reliable, real-world evidence for EU medicine assessments

- PMLiVE

Celltrion submits application for inhaled COVID-19 antibody treatment

A global phase 3 clinical study will evaluate the inhaled antibody cocktail treatment for patients with mild-to-moderate COVID-19 symptoms

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links